Citius Oncology (CTOR) Non Operating Interest Expenses (2024 - 2026)

Citius Oncology (CTOR) has reported Non Operating Interest Expenses for 3 consecutive years, with $231732.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses changed N/A year-over-year to $231732.0 in Q2 2026; TTM through Jun 2026 was $367881.0, a N/A change from a year earlier, with the FY2025 full-year figure at $5.4 million, changed N/A from the prior year.
• Non Operating Interest Expenses was $231732.0 for Q2 2026 at Citius Oncology, up from $33031.0 in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $470000.0 in Q4 2024 and troughed at $33031.0 in Q1 2026.
• A 3-year average of $167576.2 and a median of $57277.0 in 2025 frame the typical range for Non Operating Interest Expenses.
• The widest YoY moves for Non Operating Interest Expenses: up 90.25% in 2025, down 90.25% in 2025.
• Over 3 years, Non Operating Interest Expenses stood at $470000.0 in 2024, then slumped by 90.25% to $45841.0 in 2025, then jumped by 405.51% to $231732.0 in 2026.
• The last three Non Operating Interest Expenses figures came in at $231732.0 (Q2 2026), $33031.0 (Q1 2026), and $45841.0 (Q4 2025), per Business Quant data.